Default company panoramic image
Logo

Nerve Access, Inc.

$5B effective Alzheimer's therapeutic, FDA placed on expedited approval pathway, $3MM needed to file IND and conduct clinical Phase IIa.

  • Stage Product In Development
  • Industry Biotechnology
  • Location United States
  • Currency USD
  • Founded July 2008
  • Employees 6
  • Website nerveaccess.com

Company Summary

Nerve Access, Inc. is a biotechnology company that was founded to conduct quality research and manufacturing of pharmaceuticals and other medical products, with a special focus on therapeutics that can enhance regeneration and functional recovery of the Central Nervous System (CNS) after neurological disorders such as Alzheimer's, stroke, Parkinson's, spinal cord injury, multiple sclerosis, and traumatic brain injury.

Team

  • Default avatar
    Yaser A Maksoud
    President & CEO

    - Neurosurgeon, and neuroscientist who graduated from Zagazig University in Egypt in 1994.
    - Worked in the field of Neurosurgery (1995-1999) in Egypt. - Moved to Chicago in 1999 where he did a postdoctoral fellowship at Neurosurgery, University of Illinois at Chicago.
    - Taught biomedical science to graduate and undergraduate students in Chicago (2002-2006).
    - Founded Neural Repair Institute (2006) and Nerve Access (2008).

  • Default avatar
    Tony Giordano, PhD
    Director, Drug Development

    - Experienced Entrepreneur, President or V.P. of 6 biotech companies
    - Has been involved in development of four clinical products

  • Default avatar
    Mustafa Maher, Rph
    Director, Drug Formulation

    - Senior Compounding Pharmacist, Women’s International Pharmacy
    - Over twenty six years of formulation experience

Advisors

  • Default avatar
    Aaron F. Barkoff, Ph.D., Partner, McAndrews, Held & Malloy, Ltd., Intellectual Property Counsel
    Lawyer
    Unconfirmed
    Default avatar
    Abbassi Accounting
    Accountant
    Unconfirmed

Previous Investors

  • Default avatar
    Founder/Family
    Unconfirmed
    Default avatar
    Federal Grants
    Unconfirmed